Reported 1 day ago
In 2024, GLP-1 weight-loss drugs gained attention for their increased employer coverage and pricing shifts, with pharmaceutical leaders like Novo Nordisk and Eli Lilly looking to apply these drugs for conditions beyond weight management, such as heart disease and sleep apnea. As the industry approaches 2025, insights indicate significant developments on the horizon for GLP-1 therapies.
Source: YAHOO